<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00099359</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD/HPTN 040 (P1043)</org_study_id>
    <nct_id>NCT00099359</nct_id>
  </id_info>
  <brief_title>Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission</brief_title>
  <official_title>Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giving anti-HIV medications to babies born of HIV positive mothers right after birth can
      lower the babies' risk of contracting HIV. This study will assess the safety and efficacy of
      two different combinations of anti-HIV medications compared to a one drug standard regimen in
      preventing mother to baby transmission. The one drug standard treatment and two combinations
      to be studied are: 1) zidovudine, 2) zidovudine/nevirapine and 3)
      zidovudine/lamivudine/nelfinavir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the notable reductions in perinatal transmission of HIV-1 with antiretroviral therapy
      and other interventions, perinatal transmission continues to occur at rates of 20-30% among
      pregnant women who are not identified as HIV-1-infected and/or are not provided with
      antiretroviral therapy. The optimum treatment strategy for prevention of transmission of
      HIV-1 to infants born to these women is unknown. No trials have evaluated the efficacy of
      neonatal antiretroviral therapy alone but observational data suggest benefit from zidovudine
      (ZDV) therapy given to the infant beginning within 48 hours of birth and continued for six
      weeks. This protocol will compare the safety and efficacy of three antiretroviral regimens
      administered in the neonatal period: Arm A- ZDV, Arm B- ZDV plus nevirapine (NVP), and Arm C-
      ZDV plus nelfinavir (NFV) and lamivudine (3TC). Two regimens were selected based on expected
      antiretroviral activity, pharmacokinetic data, and toxicity profiles. Standard of care (6
      weeks of ZDV) alone will be compared to the 6 weeks of ZDV plus either 3 doses of NVP or 2
      weeks of 3TC and NFV. Arm B (ZDV + NVP) is the regimen expected to provide the best profile
      when factors of efficacy, safety, cost, acceptability and convenience are considered. The
      comparison of Arms B and C is also of considerable interest since the 2-drug Arm B is easier
      to implement and less expensive than the triple drug Arm C. Although triple drug therapies
      have been recommended for post-exposure prophylaxis for needle-stick injuries in high-risk
      circumstances, it is unknown whether the triple drug arm will provide better efficacy than
      the 2-drug arm for post-exposure prophylaxis of the infant.

      This open-label study is expected to accrue 1731 infants of women identified in labor as
      being HIV positive or who are HIV positive but have not received antiretroviral medication
      during the pregnancy. If eligible the infant will be randomized at birth to one of three
      aforementioned treatment arms. Medical history, social, demographic, physical exam, RNA and
      T- lymphocyte data are collected on the mother during the delivery visit. The infant will
      have a birth visit and then return for 1-week, 2-week, 4-week, 3-month and a final 6-month
      visit. Infant evaluations will include: a medical history and physical exam, DNA testing, CBC
      and liver function tests, cells for long-term storage and RNA/CD4/CD8 testing if HIV
      positive. The initial study drug doses will be given to the infant while in the hospital.
      Mothers will administer the infants' remaining treatment doses at home depending on ability.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infant HIV Infection Status</measure>
    <time_frame>3 months</time_frame>
    <description>Intrapartum HIV infection at 3 Months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Serious Adverse Events</measure>
    <time_frame>through age 6 months.</time_frame>
    <description>Serious Adverse Events by System Organ Class=Blood and lymphatic system disorders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infant HIV-1 Infection Status</measure>
    <time_frame>birth</time_frame>
    <description>In utero HIV-1 infection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Deaths</measure>
    <time_frame>through age 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Covariates of HIV-1 Infection</measure>
    <time_frame>through age 3 months</time_frame>
    <description>Compare HIV-1 RNA levels; CD4+ lymphocyte counts; and rates of genotypic and phenotypic resistance among the three treatment regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3TC and NFV Pharmacokinetics</measure>
    <time_frame>through age 14 days</time_frame>
    <description>Descriptive study of 3TC and NFV pharmacokinetics during first two weeks of life using weight band dosing regimen in a subset of enrolled infants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk Factors for Perinatal HIV-1 Transmission</measure>
    <time_frame>through age 3 months</time_frame>
    <description>Risk factors to be assessed include maternal HIV-1 RNA levels at delivery, maternal syphilis and other infections, obstetrical factors such as duration of membrane rupture, and adherence to neonatal medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NVP Pharmacokinetics</measure>
    <time_frame>14 days</time_frame>
    <description>Descriptive study of NVP pharmacokinetics during first two weeks of life using weight band dosing in a subset of enrolled infants.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1735</enrollment>
  <condition>Disease Transmission, Vertical</condition>
  <condition>Vertical Human Immunodeficiency Virus Transmission</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care ( Zidovudine only)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care (Zidovudine) plus Nevirapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of Care (Zidovudine) plus 2 weeks of Epivir and Nelfinavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>Given for 6 weeks. 12mg PO BID if birthweight (BW) &gt; 2000 grams 8 mg PO BID if BW &lt; 2000 grams</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Retrovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine (NVP)</intervention_name>
    <description>Standard of Care (Zidovudine) plus
NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :
12 mg PO per dose if BW &gt; 2000 grams, 8 mg PO per dose if BW &lt; 2000 grams</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Viramune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epivir (3TC)</intervention_name>
    <description>Stand of care (Zidovudine) plus
3TC, given for 2 weeks: 6 mg po bid if BW &gt; 2000 grams 4 mg po bid if BW &lt; 2000 grams AND
NFV, given for 2 weeks:
200 mg po bid if BW &gt; 3000 grams 150 mg po bid if BW &gt; 2,000 - 3000 grams 100 mg PO BID if BW &lt; 2000 grams</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Lamivudine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir (NFV)</intervention_name>
    <description>200 mg BID if birth weight (BW) &gt; 3000 grams for 2 weeks;150 mg BID if BW &gt; 2000-3000 grams for 2 weeks; 100 mg BID BW &lt;/= 2000 grams for 2 weeks</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Viracept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Infants who meet all of the following criteria are eligible for the study:

          -  Mother known to be HIV-1-infected prior to labor or identified at the time of labor or
             &lt;48 hours postpartum. HIV-1 infection for the purposes of enrollment into this study
             is defined as: (a) Single positive HIV-1 rapid test in mother or her infant; or (b)
             Historical documentation of a positive HIV-1 diagnostic test confirmed by repeat
             diagnostic testing for HIV-1 according to country guidelines in mother (written
             documentation of test results must be present in the medical record).

          -  Maternal written informed consent for study participation.

          -  Mother has not received any antiretroviral therapy during the current pregnancy prior
             to the onset of labor and delivery; women may have received intravenous or oral ZDV
             during labor. Women may have received any antiretroviral therapy in previous
             pregnancies for prevention of vertical HIV-1 transmission.

          -  Infant is &lt;48 hours old. Infant may have received up to 48 hours of ZDV as standard
             care before study enrollment.

        Exclusion Criteria:

        Infants who meet any of the following criteria will be excluded from the study:

          -  Extreme prematurity (&lt; 32 weeks of gestation).

          -  Birth weight &lt;1500 grams.

          -  Presence of life-threatening conditions.

          -  Inability to take oral medication throughout the first 48 hours of life (must be able
             to receive oral medication by age 48 hours).

          -  Maternal inability to provide informed consent because of a lack of a conscious state,
             psychiatric conditions, or language barriers.

          -  Mother received any antiretroviral therapy during labor and delivery other than
             intravenous or oral ZDV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karin Nielsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miller Children's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of FL</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of FL-HSC</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical and Dental School of NJ-Newark Campus</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Childrens Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital I. G. A. Dr. Diego Paroissien</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal University of Minas Gerais (UFMG)</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade de Sao Paulo (USP) , MD</name>
      <address>
        <city>São Paulo</city>
        <state>Ribeirão Preto</state>
        <zip>14024-250</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fêmina S.A. Unidade Perinatal de Transmissão Vertical</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90430001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Casa (HSC)</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90850 530</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao (GHC)</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital dos Servidores do Estado (HSE)</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20221-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Novo Iguacu</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>26030-380</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5088 - Universidade Federal de Sao Paulo (UFSP)</name>
      <address>
        <city>São Paulo</city>
        <zip>04939-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00936-8344</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nichd.nih.gov/</url>
    <description>home page of the National Institute of Child Health and Human Development</description>
  </link>
  <results_reference>
    <citation>Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Veloso VG, Rossi S, Moye J, Bryson Y, Mofenson L, Camarca M, Watts DH; NICHD HPTN 040/PACTG 1043 PROTOCOL Team. Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life. Pediatr Infect Dis J. 2011 Sep;30(9):769-72. doi: 10.1097/INF.0b013e3182242950.</citation>
    <PMID>21666540</PMID>
  </results_reference>
  <results_reference>
    <citation>Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Jiménez E, Veloso VG, Parsons T, Watts DH, Moye J, Mofenson LM, Camarca M, Bryson Y; NICHD/HPTN 040/PACTG 1043 Protocol Team. Nevirapine concentrations in newborns receiving an extended prophylactic regimen. J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):334-7.</citation>
    <PMID>18398973</PMID>
  </results_reference>
  <results_reference>
    <citation>Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Ceriotto M, Machado D, Bethel J, Morgado MG, Dickover R, Camarca M, Mirochnick M, Siberry G, Grinsztejn B, Moreira RI, Bastos FI, Xu J, Moye J, Mofenson LM; NICHD HPTN 040/PACTG 1043 Protocol Team. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012 Jun 21;366(25):2368-79. doi: 10.1056/NEJMoa1108275.</citation>
    <PMID>22716975</PMID>
  </results_reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2004</study_first_submitted>
  <study_first_submitted_qc>December 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2004</study_first_posted>
  <results_first_submitted>April 25, 2012</results_first_submitted>
  <results_first_submitted_qc>October 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2012</results_first_posted>
  <last_update_submitted>October 26, 2012</last_update_submitted>
  <last_update_submitted_qc>October 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Perinatal</keyword>
  <keyword>Prevention</keyword>
  <keyword>Transmission</keyword>
  <keyword>Nevirapine</keyword>
  <keyword>Epivir</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Nelfinavir</keyword>
  <keyword>ZDV</keyword>
  <keyword>NVP</keyword>
  <keyword>3TC</keyword>
  <keyword>NFV</keyword>
  <keyword>Viracept</keyword>
  <keyword>Viramune</keyword>
  <keyword>HIV Seronegativity</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled on 02/27/2004 and the study ended 02/28/2011. A total of 17 sites in Brazil, South Africa, Argentina and the U.S. participated in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A (ZDV Only)</title>
          <description>Standard of care ( Zidovudine only). 12 mg PO BID if BW&gt;2000 grams ; 8 mg PO BID if BW&lt;/= 2000 grams</description>
        </group>
        <group group_id="P2">
          <title>ARM B (ZDV + NVP)</title>
          <description>Standard of care (Zidovudine) plus Nevirapine (NVP)
NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :
12 mg PO per dose if BW &gt; 2000 grams, 8 mg PO per dose if BW &lt; 2000 grams</description>
        </group>
        <group group_id="P3">
          <title>ARM C (ZDV + 3TC + NFV)</title>
          <description>Standard of Care (Zidovudine) plus 2 weeks of Epivir (3TC) and Nelfinavir (NFV) 3TC, given for 2 weeks: 6 mg po bid if BW &gt; 2000 grams 4 mg po bid if BW &lt; 2000 grams AND
NFV, given for 2 weeks:
200 mg po bid if BW &gt; 3000 grams 150 mg po bid if BW &gt; 2,000 – 3000 grams 100 mg PO BID if BW &lt; 2000 grams</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="581"/>
                <participants group_id="P2" count="580"/>
                <participants group_id="P3" count="574"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="527"/>
                <participants group_id="P2" count="515"/>
                <participants group_id="P3" count="506"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="68"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>moved out of area</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A (ZDV Only)</title>
          <description>Standard of care ( Zidovudine only). 12 mg PO BID if BW&gt;2000 grams ; 8 mg PO BID if BW&lt;/= 2000 grams</description>
        </group>
        <group group_id="B2">
          <title>ARM B (ZDV + NVP)</title>
          <description>Standard of care (Zidovudine) plus Nevirapine (NVP)
NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :
12 mg PO per dose if BW &gt; 2000 grams, 8 mg PO per dose if BW &lt; 2000 grams</description>
        </group>
        <group group_id="B3">
          <title>ARM C (ZDV + 3TC + NFV)</title>
          <description>Standard of Care (Zidovudine) plus 2 weeks of Epivir (3TC) and Nelfinavir (NFV) 3TC, given for 2 weeks: 6 mg po bid if BW &gt; 2000 grams 4 mg po bid if BW &lt; 2000 grams AND
NFV, given for 2 weeks:
200 mg po bid if BW &gt; 3000 grams 150 mg po bid if BW &gt; 2,000 – 3000 grams 100 mg PO BID if BW &lt; 2000 grams</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="581"/>
            <count group_id="B2" value="580"/>
            <count group_id="B3" value="574"/>
            <count group_id="B4" value="1735"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Gestational Age in Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="1.7"/>
                    <measurement group_id="B2" value="39" spread="1.5"/>
                    <measurement group_id="B3" value="39" spread="1.7"/>
                    <measurement group_id="B4" value="39" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="303"/>
                    <measurement group_id="B3" value="281"/>
                    <measurement group_id="B4" value="882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="283"/>
                    <measurement group_id="B2" value="277"/>
                    <measurement group_id="B3" value="293"/>
                    <measurement group_id="B4" value="853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="409"/>
                    <measurement group_id="B2" value="408"/>
                    <measurement group_id="B3" value="402"/>
                    <measurement group_id="B4" value="1219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="156"/>
                    <measurement group_id="B4" value="475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Infant HIV Infection Status</title>
        <description>Intrapartum HIV infection at 3 Months</description>
        <time_frame>3 months</time_frame>
        <population>All infants with HIV-1 test results except infants infected at birth (i.e. in utero infections) were included in these analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A (ZDV - Standard of Care)</title>
            <description>ZDV (standard of care), given for 6 weeks:
12 mg PO BID if birthweight (BW) &gt; 2000 grams 8 mg PO BID if BW &lt; 2000 grams</description>
          </group>
          <group group_id="O2">
            <title>ARM B (ZDV + NVP)</title>
            <description>plus NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose : 12 mg PO per dose if BW &gt; 2000 grams, 8 mg PO per dose if BW &lt; 2000 grams</description>
          </group>
          <group group_id="O3">
            <title>ARM C (ZDV +3TC+NFV)</title>
            <description>ZDV (standard of care) plus 3TC, given for 2 weeks:
6 mg po bid if BW &gt; 2000 grams 4 mg po bid if BW &lt; 2000 grams AND
NFV, given for 2 weeks:
200 mg po bid if BW &gt; 3000 grams 150 mg po bid if BW &gt; 2,000 - 3000 grams 100 mg PO BID if BW &lt; 2000 grams</description>
          </group>
        </group_list>
        <measure>
          <title>Infant HIV Infection Status</title>
          <description>Intrapartum HIV infection at 3 Months</description>
          <population>All infants with HIV-1 test results except infants infected at birth (i.e. in utero infections) were included in these analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
                <count group_id="O2" value="562"/>
                <count group_id="O3" value="556"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.046</p_value>
            <p_value_desc>Overall comparison of 3 KM curves using an extension of the M-H test was performed. Results indicated a significant difference therefore a 2nd stage analysis was done to compare each pair of transmission rates, using 2-sample Mantel-Haenzel tests.</p_value_desc>
            <method>multiple comparison</method>
            <method_desc>Hochberg’s modified Bonferroni method was used to adjust the significance level for comparisons between arms.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Serious Adverse Events</title>
        <description>Serious Adverse Events by System Organ Class=Blood and lymphatic system disorders</description>
        <time_frame>through age 6 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARM A (ZDV Only)</title>
            <description>ZDV only</description>
          </group>
          <group group_id="O2">
            <title>ARM B (ZDV + NVP)</title>
            <description>ZDV + NVP</description>
          </group>
          <group group_id="O3">
            <title>ARM C (ZDV + 3TC/NFV)</title>
            <description>ZDV + 3TC/NFV</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Serious Adverse Events</title>
          <description>Serious Adverse Events by System Organ Class=Blood and lymphatic system disorders</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
                <count group_id="O2" value="562"/>
                <count group_id="O3" value="556"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant HIV-1 Infection Status</title>
        <description>In utero HIV-1 infection rate</description>
        <time_frame>birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (ZDV Only)</title>
            <description>Standard of care ( Zidovudine only). 12 mg PO BID if BW&gt;2000 grams ; 8 mg PO BID if BW&lt;/= 2000 grams</description>
          </group>
          <group group_id="O2">
            <title>ARM B (ZDV + NVP)</title>
            <description>Standard of care (Zidovudine) plus Nevirapine (NVP)
NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :
12 mg PO per dose if BW &gt; 2000 grams, 8 mg PO per dose if BW &lt; 2000 grams</description>
          </group>
          <group group_id="O3">
            <title>ARM C (ZDV + 3TC + NFV)</title>
            <description>Standard of Care (Zidovudine) plus 2 weeks of Epivir (3TC) and Nelfinavir (NFV) 3TC, given for 2 weeks: 6 mg po bid if BW &gt; 2000 grams 4 mg po bid if BW &lt; 2000 grams AND
NFV, given for 2 weeks:
200 mg po bid if BW &gt; 3000 grams 150 mg po bid if BW &gt; 2,000 - 3000 grams 100 mg PO BID if BW &lt; 2000 grams</description>
          </group>
        </group_list>
        <measure>
          <title>Infant HIV-1 Infection Status</title>
          <description>In utero HIV-1 infection rate</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="581"/>
                <count group_id="O2" value="580"/>
                <count group_id="O3" value="574"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.2432</p_value>
            <method>multiple comparison</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Deaths</title>
        <time_frame>through age 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (ZDV Only)</title>
            <description>Standard of care ( Zidovudine only). 12 mg PO BID if BW&gt;2000 grams ; 8 mg PO BID if BW&lt;/= 2000 grams</description>
          </group>
          <group group_id="O2">
            <title>ARM B (ZDV + NVP)</title>
            <description>Standard of care (Zidovudine) plus Nevirapine (NVP)
NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :
12 mg PO per dose if BW &gt; 2000 grams, 8 mg PO per dose if BW &lt; 2000 grams</description>
          </group>
          <group group_id="O3">
            <title>ARM C (ZDV + 3TC + NFV)</title>
            <description>Standard of Care (Zidovudine) plus 2 weeks of Epivir (3TC) and Nelfinavir (NFV) 3TC, given for 2 weeks: 6 mg po bid if BW &gt; 2000 grams 4 mg po bid if BW &lt; 2000 grams AND
NFV, given for 2 weeks:
200 mg po bid if BW &gt; 3000 grams 150 mg po bid if BW &gt; 2,000 - 3000 grams 100 mg PO BID if BW &lt; 2000 grams</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Deaths</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="581"/>
                <count group_id="O2" value="580"/>
                <count group_id="O3" value="574"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Covariates of HIV-1 Infection</title>
        <description>Compare HIV-1 RNA levels; CD4+ lymphocyte counts; and rates of genotypic and phenotypic resistance among the three treatment regimens.</description>
        <time_frame>through age 3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>3TC and NFV Pharmacokinetics</title>
        <description>Descriptive study of 3TC and NFV pharmacokinetics during first two weeks of life using weight band dosing regimen in a subset of enrolled infants.</description>
        <time_frame>through age 14 days</time_frame>
        <population>This was a descriptive study. A total of 26 infants were analyzed with 14 at age 4-7 days and 12 at 10-14 days.Plasma samples were collected prior to first AM dose and then at 1,2,4,8 and 12 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM C (ZDV + 3TC/NFV)</title>
            <description>Standard ZDV for 6 weeks combined with 2 weeks of 3TC and NFV. NFV and 3TC plasma concentrations were measured by validated HPLC assays with lower detection limit of 0.04 micrograms/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>3TC and NFV Pharmacokinetics</title>
          <description>Descriptive study of 3TC and NFV pharmacokinetics during first two weeks of life using weight band dosing regimen in a subset of enrolled infants.</description>
          <population>This was a descriptive study. A total of 26 infants were analyzed with 14 at age 4-7 days and 12 at 10-14 days.Plasma samples were collected prior to first AM dose and then at 1,2,4,8 and 12 hours.</population>
          <units>ug*h/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>(NFV-AUC-12h) 4-7 day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" spread="46.57" lower_limit="3.4" upper_limit="183.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>(NFV-AUC-12h) 10-14 day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="13.10" lower_limit="1.7" upper_limit="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>(3TC-AUC-12 h) 4-7 day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="4.50" lower_limit="2.9" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>(3TC-AUC-12h) 10-14 day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="4.12" lower_limit="2.7" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk Factors for Perinatal HIV-1 Transmission</title>
        <description>Risk factors to be assessed include maternal HIV-1 RNA levels at delivery, maternal syphilis and other infections, obstetrical factors such as duration of membrane rupture, and adherence to neonatal medication.</description>
        <time_frame>through age 3 months</time_frame>
        <population>All available demographic and clinical variables were tested for association with transmission rate. All variables that were significant at p ≤ 0.20 were included in the multivariable regression model. Variables that were not significant were then removed from the model. The backward elimination method was used to select the final model.</population>
        <group_list>
          <group group_id="O1">
            <title>Infected</title>
            <description>Infants infected after birth</description>
          </group>
          <group group_id="O2">
            <title>Uninfected</title>
            <description>Infants uninfected after birth</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for Perinatal HIV-1 Transmission</title>
          <description>Risk factors to be assessed include maternal HIV-1 RNA levels at delivery, maternal syphilis and other infections, obstetrical factors such as duration of membrane rupture, and adherence to neonatal medication.</description>
          <population>All available demographic and clinical variables were tested for association with transmission rate. All variables that were significant at p ≤ 0.20 were included in the multivariable regression model. Variables that were not significant were then removed from the model. The backward elimination method was used to select the final model.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="1544"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Arm C (ZDV+3TC/NFV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Arm B (ZDV+NFV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Arm A (ZDV only)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Illegal Substance Abuse during pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjusted Odds ratio for treatment arm C (ZDV+3TC/NFV) association with Intrapartum Infection Status with Treatment Arm A (ZDV only) as reference group</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>Adjusted odds ratio for association of treatment arm B (ZDV+NVP) with intrapartum infection status with Treatment Arm A (ZDV only) as reference.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjusted odds ratio for association of illegal substance use during pregnancy and intrapartum HIV infection status with &quot;NO&quot; being reference group.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>5.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted odds ratio for the association of continuous log10 viral load with intrapartum infection status</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.56</ci_lower_limit>
            <ci_upper_limit>3.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NVP Pharmacokinetics</title>
        <description>Descriptive study of NVP pharmacokinetics during first two weeks of life using weight band dosing in a subset of enrolled infants.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARM B (ZDV + NVP)</title>
            <description>NVP concentrations were measured in 14 infants immediately before the 3rd dose, 4 hours post dose, 1 day post dose, 3-5 days post dose and 7 days post dose.</description>
          </group>
        </group_list>
        <measure>
          <title>NVP Pharmacokinetics</title>
          <description>Descriptive study of NVP pharmacokinetics during first two weeks of life using weight band dosing in a subset of enrolled infants.</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NVP conc prior to 3rd dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362" lower_limit="165" upper_limit="1728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NVP peak conc (Cmax) post 3rd dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2286" lower_limit="1241" upper_limit="3811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NVP conc 3-5 day post 3rd dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459" lower_limit="73" upper_limit="1747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NVP conc 7 day post 3rd dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="25" upper_limit="652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through 6 months</time_frame>
      <desc>AE data collected from study entry to off study period</desc>
      <group_list>
        <group group_id="E1">
          <title>ARM A (ZDV Alone)</title>
          <description>ZDV, given for 6 weeks:
12 mg PO BID if birthweight (BW) &gt; 2000 grams 8 mg PO BID if BW &lt; 2000 grams</description>
        </group>
        <group group_id="E2">
          <title>ARM B (ZDV + NVP)</title>
          <description>ZDV, given for 6 weeks:
12 mg PO BID if birthweight (BW) &gt; 2000 grams 8 mg PO BID if BW &lt; 2000 grams
AND NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :
12 mg PO per dose if BW &gt; 2000 grams, 8 mg PO per dose if BW &lt; 2000 grams</description>
        </group>
        <group group_id="E3">
          <title>ARM C (ZDV + 3TC/NFV)</title>
          <description>ZDV, given for 6 weeks:
12 mg PO BID if birthweight (BW) &gt; 2000 grams 8 mg PO BID if BW &lt; 2000 grams AND 3TC, given for 2 weeks: 6 mg po bid if BW &gt; 2000 grams 4 mg po bid if BW &lt; 2000 grams AND
NFV, given for 2 weeks:
200 mg po bid if BW &gt; 3000 grams 150 mg po bid if BW &gt; 2,000 – 3000 grams 100 mg PO BID if BW &lt; 2000 grams</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="581"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="252" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia Nos</sub_title>
                <counts group_id="E1" events="51" subjects_affected="48" subjects_at_risk="581"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="580"/>
                <counts group_id="E3" events="46" subjects_affected="39" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Axillary Lymphadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Disseminated Intravascular Coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Isoimmune Haemolytic Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="33" subjects_at_risk="581"/>
                <counts group_id="E2" events="40" subjects_affected="33" subjects_at_risk="580"/>
                <counts group_id="E3" events="83" subjects_affected="71" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Polycythaemia Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Thrombocythaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="581"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="580"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Cyanosis Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Pulmonary Valve Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Tachycardia Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Tricuspid Valve Incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Cardiac Disorder Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Congenital Cardiac Septal Defect Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital Atrial Septal Defect</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="581"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="580"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Congenital Choroid Plexus Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Congenital Clubfoot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Congenital Cytomegalovirus Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Congenital Infection Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Congenital Macrocephaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Congenital Syphilis</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="581"/>
                <counts group_id="E2" events="52" subjects_affected="52" subjects_at_risk="580"/>
                <counts group_id="E3" events="43" subjects_affected="42" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Congenital Toxoplasmosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Congenital Ventricular Septal Defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Foetal Alcohol Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Genitalia External Ambiguous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Meningomyelocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Patent Ductus Arteriosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Retinoblastoma Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Trisomy 21</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Urethral Valves</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal Conjunctivitis Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired Pyloric Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Diarrhoea Nos</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="581"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="580"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Vomiting Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Withdrawal Syndrome Neonatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="581"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Sudden Infant Death Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Jaundice Nos</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="581"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Breast Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="581"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="580"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Bronchitis Acute Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia Nos</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="581"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="580"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Cellulitis Gangrenous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Conjunctivitis Infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Febrile Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Nos</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="581"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="580"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Impetigo Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia Nos</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection Nos</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Meningitis Pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Neonatal Infection Nos</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Omphalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Otitis Media Acute Nos</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Parainfluenzae Virus Infection Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Periorbital Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Pneumocystis Carinii Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Pneumocystis Carinii Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Pneumonia Nos</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="581"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="580"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus Infection Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Nos</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="581"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Scabies Infestation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Sepsis Neonatal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="581"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="580"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Sepsis Nos</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="581"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="580"/>
                <counts group_id="E3" events="24" subjects_affected="23" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Tuberculosis Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Umbilical Cord Sepsis Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="580"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Acoustic Stimulation Tests Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="581"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="580"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="581"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="580"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Blood Calcium Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Blood Potassium Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Blood Urea Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Cardiac Murmur Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>General Physical Condition Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Electrolyte Imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Failure To Thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Feeding Problem In Newborn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>General Nutrition Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="581"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia Nos</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Malnutrition Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Marasmus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Underweight</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tongue Neoplasm Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Thrombosis Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Convulsions Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Encephalitis Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Poor Sucking Reflex</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Visual Field Defect Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Jaundice Neonatal</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="581"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="580"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Premature Baby</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="581"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="580"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Small For Dates Baby</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="581"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="580"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Asthma Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Bronchitis Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Bronchospasm Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Cyanosis Neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Neonatal Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Obstructive Airways Disorder Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Pneumothorax Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Pulmonary Artery Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="580"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Face Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Urticaria Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Exposure To Communicable Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Social Problem Nos</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="581"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="580"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac Operation Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Eye Excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension Nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>Vasculitis Nos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="492" subjects_at_risk="581"/>
                <counts group_id="E2" subjects_affected="482" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="480" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia NOS</sub_title>
                <counts group_id="E1" events="451" subjects_affected="286" subjects_at_risk="581"/>
                <counts group_id="E2" events="402" subjects_affected="270" subjects_at_risk="580"/>
                <counts group_id="E3" events="456" subjects_affected="287" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="294" subjects_affected="225" subjects_at_risk="581"/>
                <counts group_id="E2" events="261" subjects_affected="119" subjects_at_risk="580"/>
                <counts group_id="E3" events="334" subjects_affected="244" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>oral candidiasis</sub_title>
                <counts group_id="E1" events="188" subjects_affected="162" subjects_at_risk="581"/>
                <counts group_id="E2" events="194" subjects_affected="170" subjects_at_risk="580"/>
                <counts group_id="E3" events="177" subjects_affected="156" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="439" subjects_affected="335" subjects_at_risk="581"/>
                <counts group_id="E2" events="429" subjects_affected="317" subjects_at_risk="580"/>
                <counts group_id="E3" events="418" subjects_affected="325" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Margaret Camarca, Project Director</name_or_title>
      <organization>Westat</organization>
      <phone>301-517-4128</phone>
      <email>margaretcamarca@westat.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

